As of Oct 20
| -0.04 / -3.20%|
The 4 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 1.33, with a high estimate of 4.00 and a low estimate of 1.00. The median estimate represents a +9.50% increase from the last price of 1.21.
The current consensus among 6 polled investment analysts is to Hold stock in Regulus Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.